3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
70
Thoracic
12
Head & Neck
9
Gynecologic
4
CNS
3
Breast
3
Lymphoid
2
Tumor-Agnostic
1
Sarcoma
1
Other solid neoplasm
1
Other neoplasm
1
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
1
Interventions
lutetium Lu 177 dotatate
15
Magnetic Resonance Spectroscopy
9
Everolimus
8
gallium Ga 68 dotatate
6
lanreotide
4
cabozantinib
4
Temozolomide
4
Specimen Handling
4
Nivolumab
4
Lutetium-177
4
Lutetium
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
surufatinib
3
olaparib
3
copper dotatate CU-64
3
Somatostatin
3
Injections
3
Ga(III)-DOTATOC
3
Fluorodeoxyglucose F18
3
Capecitabine
3
pembrolizumab
2
amino-acid, glucose, and electrolyte solution
2
X-Rays
2
Sunitinib
2
Radiosurgery
2
Octreotide
2
Drug Therapy
2
Cyclophosphamide
2
64Cu-DOTATATE
2
zimberelimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
sintilimab
×
NET
×
Clear all
NCT05165407
2025-03-14
NESSIE
Peking University
Phase 2
Recruiting
30 enrolled